XNAS
KMTS
Market cap1.51bUSD
Oct 08, Last price
25.77USD
1D
-2.72%
1Q
-0.85%
IPO
22.77%
Name
Kestra Medical Technologies Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Key people
Brian Webster
President, Chief Executive Officer, Founder, Director · since 2021
Vaseem Mahboob
Chief Financial Officer · since 2021
Phillip Foshee
Senior Vice President - Research & Development
Jeffrey Laub
Senior Vice President - Supply Chain Operations · since 2020
Traci Umberger
Chief Administrative Officer, General Counsel, Director · since 2021
Debra Schotz
Senior Vice President - Marketing · since 2023
Al Ford
Chief Commercial Officer
Toby AuWerter
Independent Director · since 2025
Maxwell Bikoff
Independent Director · since 2025
Independent Director · since 2025
Independent Director · since 2016
Conor Hanley
Independent Director · since 2025
Elizabeth Kwo
Independent Director · since 2025
Mary Ladone
Independent Director · since 2025
Kevin Reilly
Independent Director · since 2025
Independent Chairman of the Board · since 2023
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2026‑04 | 2025‑04 | 2024‑04 | 2023‑04 | 2021‑04 | 2020‑04 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT |